AKT1 and cancer: SYCP3 is a DNA‐binding protein and a structural component of the synaptonemal complex (Yuan et al. 1998), and SYCP3‐mediated PI3K/Akt activation appears to be highly associated with resistance of tumor cells to cancer drugs (Noh et al. 2009).